Levarium Lenvatinib Capsules 4 mg is a prescription oral oncology medicine identified as containing Lenvatinib 4 mg per capsule.

Lenvatinib is a targeted anticancer medicine classified as a multikinase inhibitor.

It inhibits several receptor tyrosine kinases involved in tumor growth and angiogenesis, including vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR).

Lenvatinib is used in selected treatment settings for differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma and endometrial carcinoma, depending on the indication and combination regimen.

The stated 4 mg capsule strength does not establish the prescribed daily dose. Different cancer indications use different dosing regimens, and the prescribed dose may require modification.

The exact manufacturer, pack size, capsule composition, storage conditions and approved indications of Levarium must be verified from its approved Indian product documentation.

Marketed by Essentials Emporium Enterprises, Levarium is listed within the oncology pharmaceutical category for hospitals, cancer treatment centres and authorized pharmaceutical buyers.

Key Product Features